The abstract is read at the publisher; the summary is JClub's.
In a multicenter trial of 89 patients with severe alcohol-associated hepatitis (MELD≥20), IL-1Ra treatment drove a day-7 IL-1Ra rise and broader cytokine shifts, while steroid therapy showed IL-1β elevation by day 28.
- Why it matters: Mortality-linked pro-inflammatory cytokines in severe alcohol-associated hepatitis have unclear time courses and treatment-specific kinetics, limiting biomarker-guided trial design and response monitoring.
- What they did: Patients from 4 US sites were randomized to anakinra (IL-1 receptor antagonist + pentoxifylline + zinc) or methylprednisolone, with plasma profiling of 43 AH-related indicators on days 0, 7, 28, 90, and 180 plus 27 healthy controls.
- The result: Dysregulated biomarkers improved in survivors but most did not normalize by day 180, and 90-day mortality–associated marker patterns differed between treatment groups, supporting treatment-specific biomarker use.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.